TY - JOUR
T1 - Erratum
T2 - Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab143)
AU - Hanzel, Jurij
AU - Dreesen, Erwin
AU - Vermeire, Séverine
AU - Löwenberg, Mark
AU - Hoentjen, Frank
AU - Bossuyt, Peter
AU - Clasquin, Esmé
AU - Baert, Filip J.
AU - D'Haens, Geert R.
AU - Mathôt, Ron
N1 - Publisher Copyright: © 2022 Oxford University Press. All rights reserved.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - In the originally published version of this manuscript, reference 36 incorrectly read "Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158:2139-2149.e14". It should have read "Sandborn WJ, Baert F, Danese S, et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158(3):562-572 e512." This has now been corrected online.
AB - In the originally published version of this manuscript, reference 36 incorrectly read "Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158:2139-2149.e14". It should have read "Sandborn WJ, Baert F, Danese S, et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158(3):562-572 e512." This has now been corrected online.
UR - http://www.scopus.com/inward/record.url?scp=85129997504&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/ibd/izab270
DO - https://doi.org/10.1093/ibd/izab270
M3 - Comment/Letter to the editor
C2 - 34788812
SN - 1078-0998
VL - 28
SP - 817
JO - Inflammatory Bowel Diseases
JF - Inflammatory Bowel Diseases
IS - 5
ER -